Top Buy Now Summary References
Home
>
Section
>
Chapter

Safety and immunogenicity of a recombinant receptor-binding domain-based protein subunit vaccine (Noora vaccine™) against COVID-19 in adults: a randomized, double-blind, placebo-controlled, Phase 1 trial

Salimian, J.; Ahmadi, A.; Amani, J.; Olad, G.; Halabian, R.; Saffaei, A.; Arabfard, M.; Nasiri, M.; Nazarian, S.; Abolghasemi, H.; Alishiri, G.

Journal of Medical Virology 95(2)

2023

ISSN/ISBN: 1096-9071
PMID: 36029105
Accession: 080229238

Full-Text Article emailed within 1 workday
Payments are secure & encrypted
Powered by Stripe
Powered by PayPal

Summary
The development of a safe and effective vaccine is essential to protect populations against coronavirus disease 2019 (COVID-19). There are several vaccine candidates under investigation with different mechanisms of action. In the present study, we have evaluated the safety and immunogenicity of a recombinant receptor-binding domain (RBD)-based protein subunit vaccine (Noora vaccine) against COVID-19 in adults. This Phase 1 trial is a randomized, double-blind, placebo-controlled study to evaluate the safety and immunogenicity of the recombinant RBD-based protein subunit vaccine (Noora vaccine) against COVID-19 in healthy adults volunteers. Eligible participants were included in this study after evaluating their health status and considering the exclusion criteria. They were then randomized into three groups and received three doses of vaccine (80 µg, 120 µg, and placebo) on Days 0, 21, and 35. Primary outcomes including solicited, unsolicited, and medically attended adverse events were recorded during this study. Secondary outcomes including the humoral and cellular immunity (including anti-RBD IgG antibody and neutralizing antibody) were measured on Days 0, 21, 28, 35, 42, and 49 by using the ELISA kit and the Virus Neutralization Test (VNT) was performed on day 49. Totally 70 cases were included in this Phase 1 trial and 60 of them completed the study. Safety assessments showed no severe adverse events. Local pain at the vaccine injection site occurred in 80% of the vaccinated volunteers. Induration and redness at the injection site were the other adverse reactions of this vaccine. There was no significant difference between the studied groups regarding adverse reactions. Anti-RBD IgG antibody and neutralizing antibody assessment showed significant seroconversion in comparison to the placebo group (80%, and 100% respectively, p < 0.001). The cellular immunity panel also showed mild to moderate induction of TH1 responses and the VNT showed 78% of seroprotection. The results of this Phase 1 trial showed acceptable safety without serious adverse events and significant seroconversions in the humoral and cellular immunity panel. The dose of 80 µg is an appropriate dose for injection in the next phases of the trial.

References

2024: Retraction: "Safety and immunogenicity of a recombinant receptor-binding domain-based protein subunit vaccine (Noora vaccine™) against COVID-19 in adults: a randomized, double-blind, placebo-controlled, Phase 1 trial" Journal of Medical Virology 96(3): E29509
Dodaran, M.S.; Banihashemi, S.R.; Es-Haghi, A.; Mehrabadi, M.H.F.; Nofeli, M.; Mokarram, A.R.; Mokhberalsafa, L.; Sadeghi, F.; Ranjbar, A.; Ansarifar, A.; Mohazzab, A.; Setarehdan, S.A.; Bagheri Amiri, F.; Mohseni, V.; Hajimoradi, M.; Ghahremanzadeh, N.; Razzaz, S.H.; Masoomi, S.; Taghdiri, M.; Bagheri, M.; Lofti, M.; Khorasani, A.; Ghader, M.; Safari, S.; Shahsavn, M.; Kalantari, S. 2023: Immunogenicity and Safety of a Combined Intramuscular/Intranasal Recombinant Spike Protein COVID-19 Vaccine (RCP) in Healthy Adults Aged 18 to 55 Years Old: a Randomized, Double-Blind, Placebo-Controlled, Phase i Trial Vaccines 11(2)
Zhang, J.; Hu, Z.; He, J.; Liao, Y.; Li, Y.; Pei, R.; Fang, X.; Zeng, P.; Fan, R.; Ou, Z.; Deng, J.; Zhou, J.; Guan, W.; Min, Y.; Deng, F.; Peng, H.; Zhang, Z.; Feng, C.; Xin, B. 2021: Safety and immunogenicity of a recombinant interferon-armed RBD dimer vaccine (V-01) for COVID-19 in healthy adults: a randomized, double-blind, placebo-controlled, Phase i trial Emerging Microbes and Infections 10(1): 1589-1597
Richmond, P.; Hatchuel, L.; Dong, M.; Ma, B.; Hu, B.; Smolenov, I.; Li, P.; Liang, P.; Han, H.H.; Liang, J.; Clemens, R. 2021: Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial Lancet 397(10275): 682-694
Yang, S.; Li, Y.; Dai, L.; Wang, J.; He, P.; Li, C.; Fang, X.; Wang, C.; Zhao, X.; Huang, E.; Wu, C.; Zhong, Z.; Wang, F.; Duan, X.; Tian, S.; Wu, L.; Liu, Y.; Luo, Y.; Chen, Z.; Li, F.; Li, J.; Yu, X.; Ren, H.; Liu, L.; Meng, S.; Yan, J.; Hu, Z.; Gao, L.; Gao, G.F. 2021: Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials LANCET. Infectious Diseases 21(8): 1107-1119
Shu, Y.-J.; He, J.-F.; Pei, R.-J.; He, P.; Huang, Z.-H.; Chen, S.-M.; Ou, Z.-Q.; Deng, J.-L.; Zeng, P.-Y.; Zhou, J.; Min, Y.-Q.; Deng, F.; Peng, H.; Zhang, Z.; Wang, B.; Xu, Z.-H.; Guan, W.-X.; Hu, Z.-Y.; Zhang, J.-K. 2021: Immunogenicity and safety of a recombinant fusion protein vaccine (V-01) against coronavirus disease 2019 in healthy adults: a randomized, double-blind, placebo-controlled, phase Ii trial Chinese Medical Journal 134(16): 1967-1976
Sokal, E.M.; Hoppenbrouwers, K.; Vandermeulen, C.; Moutschen, M.; Léonard, P.; Moreels, A.; Haumont, M.èl.; Bollen, A.; Smets, F.ço.; Denis, M. 2007: Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults Journal of Infectious Diseases 196(12): 1749-1753
Hannawi, S.; Saifeldin, L.; Abuquta, A.; Alamadi, A.; Mahmoud, S.A.; Hassan, A.; Liu, D.; Yan, L.; Xie, L. 2023: Safety and immunogenicity of a bivalent SARS-CoV-2 protein booster vaccine, SCTV01C, in adults previously vaccinated with mRNA vaccine: a randomized, double-blind, placebo-controlled phase 1/2 clinical trial Ebiomedicine 87: 104386
Hannawi, S.; Saf Eldin, L.; Abuquta, A.; Alamadi, A.; Mahmoud, S.A.; Li, J.; Chen, Y.; Xie, L. 2023: Safety and immunogenicity of a bivalent SARS-CoV-2 protein booster vaccine, SCTV01C in adults previously vaccinated with inactivated vaccine: a randomized, double-blind, placebo-controlled phase 1/2 clinical trial Journal of Infection 86(2): 154-225
Xu, X.; Yu, R.; Xiao, L.; Wang, J.; Yu, M.; Xu, J.; Tan, Y.; Ma, X.; Wu, X.; Lian, J.; Huang, K.; Ouyang, X.; Bi, S.; Wu, S.; Wang, X.; Jin, J.; Yu, L.; Zhang, H.; Wei, Q.; Shi, J.; Chen, W.; Li, L. 2021: Safety and Immunogenicity of a Recombinant Tetanus Vaccine in Healthy Adults in China: a Randomized, Double-Blind, Dose Escalation, Placebo- and Positive-Controlled, Phase 1/2 Trial Advanced Science 8(15): E2002751
Lioznov, D.; Amosova, I.; Sheetikov, S.A.; Zornikova, K.V.; Serdyuk, Y.; Efimov, G.A.; Tsyferov, M.; Khmelevskii, M.; Afanasiev, A.; Khomyakova, N.; Zubkov, D.; Tikhonov, A.; Zhu, T.; Barreto, L.; Dzutseva, V. 2023: Immunogenicity and safety of a recombinant adenovirus type-5 COVID-19 vaccine in adults: Data from a randomised, double-blind, placebo-controlled, single-dose, phase 3 trial in Russia PLOS one 18(3): E0278878
Fischer, P.; Pawlowski, A.; Cao, D.; Bell, D.; Kitson, G.; Darsley, M.; Johansson-Lindbom, B. 2021: Safety and immunogenicity of a prototype recombinant alpha-like protein subunit vaccine (GBS-NN) against Group B Streptococcus in a randomised placebo-controlled double-blind phase 1 trial in healthy adult women Vaccine 39(32): 4489-4499
Zhu, F.-C.; Guan, X.-H.; Li, Y.-H.; Huang, J.-Y.; Jiang, T.; Hou, L.-H.; Li, J.-X.; Yang, B.-F.; Wang, L.; Wang, W.-J.; Wu, S.-P.; Wang, Z.; Wu, X.-H.; Xu, J.-J.; Zhang, Z.; Jia, S.-Y.; Wang, B.-S.; Hu, Y.; Liu, J.-J.; Zhang, J.; Qian, X.-A.; Li, Q.; Pan, H.-X.; Jiang, H.-D.; Deng, P.; Gou, J.-B.; Wang, X.-W.; Wang, X.-H.; Chen, W. 2020: Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial Lancet 396(10249): 479-488
Reither, K.; Katsoulis, L.; Beattie, T.; Gardiner, N.; Lenz, N.; Said, K.; Mfinanga, E.; Pohl, C.; Fielding, K.L.; Jeffery, H.; Kagina, B.M.; Hughes, E.J.; Scriba, T.J.; Hanekom, W.A.; Hoff, S.ør.T.; Bang, P.; Kromann, I.; Daubenberger, C.; Andersen, P.; Churchyard, G.J. 2014: Safety and immunogenicity of H1/IC31®, an adjuvanted TB subunit vaccine, in HIV-infected adults with CD4+ lymphocyte counts greater than 350 cells/mm3: a phase II, multi-centre, double-blind, randomized, placebo-controlled trial Plos one 9(12): E114602
Jin, Z.; Wu, J.; Wang, Y.; Huang, T.; Zhao, K.; Liu, J.; Wang, H.; Zhu, T.; Gou, J.; Huang, H.; Wu, X.; Yin, H.; Song, J.; Li, R.; Zhang, J.; Li, L.; Chen, J.; Li, X.; Zhang, M.; Li, J.; Hou, M.; Song, Y.; Wang, B.; Gao, Q.; Wu, L.; Kong, Y.; Dong, R. 2023: Safety and immunogenicity of the COVID-19 mRNA vaccine CS-2034: a randomized, double-blind, dose-exploration, placebo-controlled multicenter Phase i clinical trial in healthy Chinese adults Journal of Infection 87(6): 556-570
Wang, G.; Zhao, K.; Han, J.; Hu, Z.; Zhang, T.; Wang, Y.; Shi, R.; Li, Y.; Song, Q.; Du, H.; He, P.; Xu, S.; Yang, X.; Fu, Y.; Cui, Y.; Xie, L. 2023: Safety and immunogenicity of a bivalent SARS-CoV-2 recombinant protein vaccine, SCTV01C in unvaccinated adults: a randomized, double-blinded, placebo-controlled, phase i clinical trial Journal of Infection 86(2): 154-225
Tkachuk, A.P.; Bykonia, E.N.; Popova, L.I.; Kleymenov, D.A.; Semashko, M.A.; Chulanov, V.P.; Fitilev, S.B.; Maksimov, S.L.; Smolyarchuk, E.A.; Manuylov, V.A.; Vasina, D.V.; Gushchin, V.A.; Gintsburg, A.L. 2020: Safety and Immunogenicity of the GamTBvac, the Recombinant Subunit Tuberculosis Vaccine Candidate: a Phase II, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study Vaccines 8(4)
Wynne, C.; Balgos, A.; Li, J.; Hamilton, P.; Tirador, L.; Jaen, A.M.; Mo, C.; Yue, Z.; Ma, Y.; Wang, Q.; Wen, R.; Yao, Z.; Yu, J.; Yao, W.; Zhang, J.; Zheng, H.; Hong, K.; Zhu, F.; Liu, Y. 2024: Safety and Immunogenicity of a Recombinant Two-Component SARS-CoV-2 Protein Vaccine: Randomized, Double-Blind, Placebo-Controlled Phase i and Phase Ii Studies Infectious Diseases and Therapy 13(1): 57-78
Abarca, K.; Rey-Jurado, E.; Muñoz-Durango, N.; Vázquez, Y.; Soto, J.A.; Gálvez, N.ás.M.S.; Valdés-Ferrada, J.; Iturriaga, C.; Urzúa, M.; Borzutzky, A.; Cerda, J.; Villarroel, L.; Madrid, V.; González, P.A.; González-Aramundiz, J.é V.; Bueno, S.M.; Kalergis, A.M. 2020: Safety and immunogenicity evaluation of recombinant BCG vaccine against respiratory syncytial virus in a randomized, double-blind, placebo-controlled phase i clinical trial Eclinicalmedicine 27: 100517
Gao, L.; Li, Y.; He, P.; Chen, Z.; Yang, H.; Li, F.; Zhang, S.; Wang, D.; Wang, G.; Yang, S.; Gong, L.; Ding, F.; Ling, M.; Wang, X.; Ci, L.; Dai, L.; Gao, G.F.; Huang, T.; Hu, Z.; Ying, Z.; Sun, J.; Zuo, X. 2023: Safety and immunogenicity of a protein subunit COVID-19 vaccine (ZF2001) in healthy children and adolescents aged 3-17 years in China: a randomised, double-blind, placebo-controlled, phase 1 trial and an open-label, non-randomised, non-inferiority, phase 2 trial LANCET. Child and Adolescent Health 7(4): 269-279